GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity Pub Date : 2024-12-22 DOI:10.1002/oby.24172

Kristen M. Beavers, Tiffany M. Cortes, Colleen M. Foy, Lauren Dinkla, Fernando Reyes San Martin, Jamy D. Ard, Monica C. Serra, Daniel P. Beavers

{"title":"GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials","authors":"Kristen M. Beavers, Tiffany M. Cortes, Colleen M. Foy, Lauren Dinkla, Fernando Reyes San Martin, Jamy D. Ard, Monica C. Serra, Daniel P. Beavers","doi":"10.1002/oby.24172","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The objective of this study was to evaluate the effect of glucagon-like peptide-1 receptor agonist (GLP1Ra)-based therapies on change in dual-energy x-ray absorptiometry (DXA)-acquired lean mass (LM) or bone mineral density (BMD).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>PubMed and Web of Science were searched from database inception through January 29, 2024, for randomized, placebo-controlled trials reporting on change in DXA-acquired LM or BMD measures associated with 12+ weeks of GLP1Ra-based treatment. Of 2618 articles, 9 trials met prespecified search criteria, with 7 reporting on change in total body LM and 2 reporting on change in BMD. For LM outcomes, a hierarchical Bayesian model was used to estimate treatment mean differences. BMD outcomes were described narratively.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>LM was reported in a total of 659 participants (GLP1Ra-based therapies: <i>n</i> = 419; placebo: <i>n</i> = 240), with follow-up times ranging from mean (SD) 12 to 72 (33.5) weeks. At baseline, participants were aged mean (SD) 41.7 (7.6) years, and 75% were female, with BMI values ranging from 30 to 43 kg/m<sup>2</sup>. Compared with placebo, GLP1Ra-based treatment was associated with significantly reduced total body weight (−6.9 kg; 95% credible interval [CI]: −10.7 to −3.0). GLP1Ra-based treatment was also associated with significantly reduced LM (−1.9 kg; 95% CI: −3.5 to −0.2).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Approximately 30% of body weight lost with GLP1Ra-based therapy is LM. More data are needed assessing BMD outcomes.</p>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 2","pages":"225-237"},"PeriodicalIF":4.2000,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774015/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.24172","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The objective of this study was to evaluate the effect of glucagon-like peptide-1 receptor agonist (GLP1Ra)-based therapies on change in dual-energy x-ray absorptiometry (DXA)-acquired lean mass (LM) or bone mineral density (BMD).

Methods

PubMed and Web of Science were searched from database inception through January 29, 2024, for randomized, placebo-controlled trials reporting on change in DXA-acquired LM or BMD measures associated with 12+ weeks of GLP1Ra-based treatment. Of 2618 articles, 9 trials met prespecified search criteria, with 7 reporting on change in total body LM and 2 reporting on change in BMD. For LM outcomes, a hierarchical Bayesian model was used to estimate treatment mean differences. BMD outcomes were described narratively.

Results

LM was reported in a total of 659 participants (GLP1Ra-based therapies: n = 419; placebo: n = 240), with follow-up times ranging from mean (SD) 12 to 72 (33.5) weeks. At baseline, participants were aged mean (SD) 41.7 (7.6) years, and 75% were female, with BMI values ranging from 30 to 43 kg/m². Compared with placebo, GLP1Ra-based treatment was associated with significantly reduced total body weight (−6.9 kg; 95% credible interval [CI]: −10.7 to −3.0). GLP1Ra-based treatment was also associated with significantly reduced LM (−1.9 kg; 95% CI: −3.5 to −0.2).

Conclusions

Approximately 30% of body weight lost with GLP1Ra-based therapy is LM. More data are needed assessing BMD outcomes.

Abstract Image

查看原文本刊更多论文

基于glp1ra的疗法和dxa获得的肌肉骨骼健康结果：安慰剂对照试验的集中荟萃分析

目的：本研究的目的是评估胰高血糖素样肽-1受体激动剂（GLP1Ra）为基础的治疗对双能x线吸收仪（DXA）获得性瘦质量（LM）或骨矿物质密度（BMD）变化的影响。方法：检索PubMed和Web of Science从数据库建立到2024年1月29日的随机、安慰剂对照试验，报告dxa获得的LM或BMD测量与12周以上glp1ra治疗相关的变化。在2618篇文章中，9篇试验符合预定的检索标准，其中7篇报道了总体LM的变化，2篇报道了BMD的变化。对于LM结果，使用分层贝叶斯模型来估计治疗平均差异。对BMD结果进行叙述。结果：共有659名参与者报告了LM(基于glp1ra的治疗：n = 419；安慰剂：n = 240)，随访时间从平均（SD） 12到72（33.5）周不等。基线时，参与者平均年龄（SD）为41.7（7.6）岁，75%为女性，BMI值在30至43 kg/m2之间。与安慰剂相比，基于glp1ra的治疗显著降低了总体重(-6.9 kg；95%可信区间[CI]: -10.7 ~ -3.0)。基于glp1ra的治疗也与显著降低的LM (-1.9 kg；95% CI: -3.5 ~ -0.2)。结论：通过glp1ra为基础的治疗，大约30%的体重减轻是LM。评估骨密度结果需要更多的数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity 医学-内分泌学与代谢

CiteScore

11.70

自引率

1.40%

发文量

261

审稿时长

2-4 weeks

期刊介绍： Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.